title: Inclusion of spleen in pediatric multivisceral transplantation.
abstract: Inclusion of the donor spleen may be beneficial for small children who receive multivisceral transplantation (MVT) because asplenia is associated with increased risk of bacterial sepsis. Beginning in 2003, the spleen was transplanted together with multivisceral transplantation in 17 children under daclizumab induction (spleen group). The results were compared to 23 children who received multivisceral transplantation without the spleen (control group) with the same immunosuppression regimen. Median age of 17 patients who received a spleen was 0.80 years (range 0.54-1.66). Platelet counts at 30 and 60 days posttransplant were significantly lower in the spleen group (average values: day 30: 399,000 vs 636,000, P = .015; day 60: 413,000 vs 622,000, P = .0056). WBC counts at 30 and 60 days posttransplant were also decreased in the spleen group but the difference was not statistically significant. Median rejection-free survival was 205 days in the spleen group and 101 days in the control group (P = NS). Median length of hospital stay was 39 days in the spleen group and 61 days in the control group. With a median follow-up of 398 days (spleen group) and 1232 days (control group), 3 of 17 (17%) in the spleen group developed graft versus host disease (GVHD), whereas 1 of 23 (4.5%) in control group did (P = NS). In one patient in each group, GVHD was fatal. No patient developed posttransplant lymphoproliferative disorder (PTLD) in the spleen group, whereas 4 of 23 (17%) in the control group developed PTLD. One-year patient survival was 84% in the spleen group and 86% in the control group. Recipients of the spleen as part of a multivisceral graft had significantly lower platelet counts. Rejection-free survival may be prolonged, but the risk of GVHD may be increased.
authors.affiliation: Divisions of Transplant, Pediatric Gastroenterology, Pediatric Critical Care Medicine, and Immunopathology, University of Miami, School of Medicine, 1801 NW 9th Avenue, Miami, FL 33136, USA. tkato@med.miami.edu
authors.forename: T
authors.initials: T
authors.lastname: Kato
authors.forename: G
authors.initials: G
authors.lastname: Kleiner
authors.forename: A
authors.initials: A
authors.lastname: David
authors.forename: G
authors.initials: G
authors.lastname: Selvaggi
authors.forename: S
authors.initials: S
authors.lastname: Nishida
authors.forename: J
authors.initials: J
authors.lastname: Madariaga
authors.forename: J
authors.initials: J
authors.lastname: Thompson
authors.forename: P
authors.initials: P
authors.lastname: Ruiz
authors.forename: A
authors.initials: A
authors.lastname: Tzakis
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001663:Bilirubin / Q000097:blood; D002675:Child, Preschool; D000077561:Daclizumab; D018572:Disease-Free Survival; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D007902:Length of Stay; D013154:Spleen / Q000637:transplantation*; D016019:Survival Analysis; D014184:Transplantation, Homologous / Q000276:immunology / Q000401:mortality; D014781:Viscera / Q000637:transplantation*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D001663:Bilirubin